Showing results (141-150 of 245) with videos related to
Sort By:
Pageof 25
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 29, 2019
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and managementNajeebah A Bade, Crystal Lu, Ciera L Patzke, et al.Blood|December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222Joseph O Moore, Stephen L George, Richard K Dodge, et al.Leukemia|April 16, 2025
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trialAjibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid LeukemiaMaria R Baer, Aksinija A Kogan, Søren M Bentzen, et al.Clinical Lymphoma, Myeloma & Leukemia|June 8, 2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesManish R Patel, William Donnellan, Michael Byrne, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2017
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal DegradationShivani Kapoor, Karthika Natarajan, Patrick R Baldwin, et al.Blood|August 1, 2002
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Richard K Dodge, et al.Cancer Chemotherapy and Pharmacology|August 17, 2013
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemiasIvana Gojo, Mariola Sadowska, Alison Walker, et al.Journal of Medicinal Chemistry|March 18, 2005
Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agentsIwao Ojima, Christopher P Borella, Xinyuan Wu, et al.Blood Advances|September 9, 2024
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosisChenyu Lin, Anand A Patel, Dezheng Huo, et al.Pageof 25